Duchenne Muscular Dystrophy — Deal Benchmarks & Valuation
Market Analysis
Duchenne Muscular Dystrophy is one of the most actively transacted indications in rare disease licensing. Phase 1 deals for duchenne muscular dystrophy carry a median total deal value of $1.0B, with upfront payments ranging from $44M to $188M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for duchenne muscular dystrophy deals allocate $327M to development milestones, $252M to regulatory milestones, and $355M to commercial milestones. Royalty rates range from 6% to 11.9% at the base tier, with tiered escalation reaching 10%-15.9% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for duchenne muscular dystrophy licensing?
What royalty rates are standard for duchenne muscular dystrophy deals?
How are duchenne muscular dystrophy deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.